ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q3Scopus Q1SCImago #4,578Hybrid

Pharmacoepidemiology and Drug Safety

Acronym:pds
•
Abbreviation (ISO):Pharmacoepidemiol. Drug Saf
•
Identifier (ISSN):1053-8569(Print)/1099-1557(Online)
•
Publisher:John Wiley and Sons Ltd
Clarivate IF (2026)
2.6↑ +0.2
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Pharmacoepidemiology and Drug Safety

WoS Q3
12342.3120182.8720192.9220202.8920212.7320222.620232.420242.420252.62026
Annual Impact Factor Metric
Current (2026):2.6
Scopus SJR & RankScopus Q1
1.041
#4,578

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
117

117 papers with at least that number of citations each

WoS: SCIE / JCRQ3
Self-Citation Rate4.2%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
166articles/year
56.11% Gold OA•88.41% Original Research

Aims & Scope

The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.

Topics Covered (Recognized by AI)
Medicine94.1%Biology80.8%Pharmacology67.4%Internal medicine62.9%Nursing60.2%Medical prescription56.1%Pharmacoepidemiology49.3%Pathology42.8%Psychology42.5%Mathematics40.5%Psychiatry39.6%Statistics36.7%Environmental health24.5%Surgery24.4%Sociology24.1%Computer science23.3%Genetics23.1%Drug21.9%Chemistry21.8%Demography21.4%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q3
Rank195/356
IndexSCIE
JCRSCIE2026

PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Q2
Rank173/443
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank178/356
IndexSCIE
JCISCIE2026

PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Q3
Rank222/443
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF2.6
Articles / Year160
Total Citations19
2025
IF2.4
Articles / Year245
Total Citations464
2024
IF2.4
Articles / Year216
Total Citations811
2023
IF2.6
Articles / Year187
Total Citations1,119
2022
IF2.732
Articles / Year200
Total Citations2,116

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #4,578Scopus Q1SCImago Profile
Scopus Coverage:1992-2026
Scopus Broad Areas:Medicine
Scopus Citation Rank (SJR)Q1
1.041

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
2.39

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,342 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,332
3-Year Documents537
Citable Documents488

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate50.4%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Pharmacology (medical)Q1
EpidemiologyQ2
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 4.2%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Pharmacoepidemiology and Drug Safety (acronym: pds, abbr: Pharmacoepidemiol. Drug Saf, ISSN: 1053-8569) is a peer-reviewed international scholarly journal in the field of Medicine, published by John Wiley and Sons Ltd in England since 1992. The periodical holds a Journal Impact Factor (JIF) of 2.60, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 1.041 (Q1), an H-index of 117.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 166 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,342 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
John Wiley and Sons Ltd
Publication Language
English
Frequency
Bimonthly
Founding Year
1992
Indexing & Databases
SCIEScopusPubMed
Editorial Address
JOHN WILEY & SONS LTD, THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: aeb67fa5-4851-4640-b570-a1b16f46371d
Database Updated: 2026-09-29